Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release

Journal Article · Tue Jul 21 00:00:00 EDT 2015 · NeuroImage

DOI:https://doi.org/10.1016/j.neuroimage.2015.07.035· OSTI ID:1239786

Volkow, Nora D. ^[1]; Wang, Gene-Jack ^[2]; Smith, Lisa ^[2]; Fowler, Joanna S. ^[3]; Telang, Frank ^[2]; Logan, Jean ^[2]; Tomasi, Dardo ^[2]

---

1. National inst. on Alcohol Abuse and Alcoholism, Bethesda, MD (United States); Brookhaven National Lab. (BNL), Upton, NY (United States)
2. National inst. on Alcohol Abuse and Alcoholism, Bethesda, MD (United States)
3. Brookhaven National Lab. (BNL), Upton, NY (United States)

Methamphetamine’s widespread abuse and concerns that it may increase Parkinson’s disease led us to assess if the reported loss of dopamine transporters (DAT) in methamphetamine abusers (MA) reflected damage to dopamine neurons. Using PET with [¹¹C]cocaine to measure DAT, and with [¹¹C]raclopride to measure dopamine release (assessed as changes in specific binding of [¹¹C]raclopride between placebo and methylphenidate), which was used as marker of dopamine neuronal function, we show that MA (n=16), tested during early detoxification, had lower DAT (20-30%) but overall normal DA release in striatum (except for a small decrease in left putamen), when compared to controls (n=15). In controls, DAT were positively correlated with DA release (higher DAT associated with larger DA increases), consistent with DAT serving as markers of DA terminals. In contrast, MA showed a trend for a negative correlation (p=0.07) (higher DAT associated with lower DA increases), consistent with reduced DA re-uptake following DAT downregulation. MA who remained abstinent nine-months later (n=9) showed significant increases in DAT (20%) but methylphenidate-induced dopamine increases did not change. In contrast, in controls, DAT did not change when retested 9 months later but methylphenidate-induced dopamine increases in ventral striatum were reduced (p=0.05). Baseline D2/D3 receptors in caudate were lower in MA than in controls and did not change with detoxification, nor did they change in the controls upon retest. The loss of DAT in the MA, which was not associated with a concomitant reduction in dopamine release as would have been expected if DAT loss reflected DA terminal degeneration; as well as the recovery of DAT after protracted detoxification, which was not associated with increased dopamine release as would have been expected if DAT increases reflected terminal regeneration, indicate that the loss of DAT in these MA does not reflect degeneration of dopamine terminals.

• Research Organization: Brookhaven National Laboratory (BNL), Upton, NY (United States)
• Sponsoring Organization: National Institute of Health, Bethesda, MD (United States)
• Grant/Contract Number: SC0012704
• OSTI ID: 1239786
• Report Number(s): BNL--111679-2015-JA
• Journal Information: NeuroImage, Journal Name: NeuroImage Journal Issue: C Vol. 121; ISSN 1053-8119
• Publisher: Elsevier
• Country of Publication: United States
• Language: English

Related Subjects

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
Parkinson's disease
addiction
dopamine terminal
neurotoxicity